# Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

Source: https://onco.cc/trials/nct04659603/  
OnCo record `nct04659603` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tusamitamab ravtansine and Gemcitabine in Breast cancer, run by Sanofi, recorded as terminated on the registry.

## Summary

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors is a phase 2 interventional study registered as NCT04659603 by Sanofi, with 50 participants recorded, started 2021-03-29 and due to reach its primary completion in 2024-02-16. Interventions recorded: tusamitamab ravtansine, Gemcitabine. Conditions recorded: Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic.

Linked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04659603
- Phase: 2
- Setting: Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
- Sponsor: Sanofi
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT04659603: https://clinicaltrials.gov/study/NCT04659603

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Tusamitamab ravtansine](https://onco.cc/drugs/tusamitamab-ravtansine/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct04659603.json